XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.23.3

Intangible assets and goodwill | 9 Months Ended
--- | ---
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible assets and goodwill | Intangible assets and goodwill The Company's finite-lived intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's finite-lived intangible assets:
| Weighted Average Useful Life in Years |  | September 30, 2023 |  | December 31, 2022
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount (1) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Products (2) | 13.5 |  | $ | 855.4 |  |  | $ | 272.6 |  |  | $ | 582.8 |  |  | $ | 982.1 |  |  | $ | 253.3 |  |  | $ | 728.8 |
Customer relationships | 0.0 |  | 28.6 |  |  | 28.6 |  |  | — |  |  | 28.6 |  |  | 28.6 |  |  | — |
CDMO | 0.0 |  | 5.5 |  |  | 5.5 |  |  | — |  |  | 5.5 |  |  | 5.5 |  |  | — |
Total intangible assets |  |  | $ | 889.5 |  |  | $ | 306.7 |  |  | $ | 582.8 |  |  | $ | 1,016.2 |  |  | $ | 287.4 |  |  | $ | 728.8 |
(1) During the nine months ended September 30, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business.
(2) During the three months ended September 30, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga TM treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022.
Amortization expense associated with the Company's intangible assets was recorded as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Amortization expense | $ | 16.3 |  |  | $ | 14.0 |  |  | $ | 49.4 |  |  | $ | 42.0 |
The table below summarizes the changes in the carrying amount of goodwill by reportable segment:
| Products (1) |  | Services (2) |  | Total
Balance at December 31, 2022 | $ | 218.2 |  |  | $ | — |  |  | $ | 218.2 |
Goodwill impairment | (218.2) |  |  | — |  |  | (218.2) |
Balance at September 30, 2023 | $ | — |  |  | $ | — |  |  | $ | — |
(1) Amounts for the Company's Products segment include gross carrying values of $259.9 million as of September 30, 2023 and December 31, 2022 and accumulated impairment losses of $259.9 million.
(2) Amounts for the Company's Services segment include gross carrying values of $6.7 million as of September 30, 2023 and December 31, 2022, and accumulated impairment losses of $6.7 million.
The Company performs its goodwill impairment evaluation annually, during the fourth quarter, or sooner if triggering events are identified. During the three months ended September 30, 2023, the Company observed continued market volatility including significant declines in its market capitalization and revised its financial outlook during the third quarter of 2023, which was identified as a triggering event. As a result of the quantitative assessments performed in connection with the preparation of the financial statements as of and for the quarter ended September 30, 2023, the Company recorded a $218.2 million non-cash goodwill impairment charge for the MCM reporting unit within the Products segment, which is included in "Goodwill impairment" on the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2023. The MCM reporting unit and Products segment had no remaining goodwill as of September 30, 2023. The goodwill impairment charge resulted from a reduction in the estimated fair value of the MCM reporting unit due to changes in the risk profile of the Company as well as revisions to the long-term operating plan that reflected lower expectations for growth and profitability than previous expectations. The Company used a quantitative assessment, utilizing an income-based (discounted cash flows) approach, Level 3 non-recurring fair value measurement, for its goodwill impairment testing.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration